Page last updated: 2024-09-04

irofulven and Lassitude

irofulven has been researched along with Lassitude in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
DeVore, RF; Dowell, JE; Johnson, DH; Krozely, P; McCullough, N; Rogers, JS; Shyr, Y1
Alberti, D; Arzoomanian, R; Bailey, H; Binger, K; Feierabend, C; MacDonald, J; Marnocha, R; Smith, C; Smith, S; Steele, T; Thomas, JP; Tutsch, KD; Wilding, G1

Trials

2 trial(s) available for irofulven and Lassitude

ArticleYear
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.
    Investigational new drugs, 2001, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Sesquiterpenes; Thrombocytopenia; Toxicity Tests; Treatment Outcome; Vomiting

2001
Phase I clinical and pharmacokinetic trial of irofulven.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:6

    Topics: Acidosis; Aged; Anorexia; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Sesquiterpenes; Vomiting

2001